Characterization and antiproliferative activity of glioma-derived extracellular vesicles

• Published in: Nanomedicine (London, England) Vol. 15; no. 10; pp. 1001 - 1018
• Main Authors: Scholl, Juliete Nathali, de Fraga Dias, Amanda, Pizzato, Pauline Rafaela, Lopes, Daniela Vasconcelos, Moritz, Cesar Eduardo Jacintho, Jandrey, Elisa Helena Farias, Souto, Gabriele Dadalt, Colombo, Mariana, Rohden, Francieli, Sévigny, Jean, Pohlmann, Adriana Raffin, Guterres, Sílvia Stanisçuaski, Battastini, Ana Maria Oliveira, Figueiró, Fabrício
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01-04-2020
• Subjects: Antigens; cancer; Chemokines; Chemotherapy; Cytokines; Extracellular vesicles; Glioma; Immune system; Lymphocytes; Medical prognosis; Penicillin; regulatory cells; tumor microenvironment; United Kingdom > UK; United States > US; glioma; cancer; extracellular vesicles; tumor microenvironment; regulatory cells
• ISSN: 1743-5889; 1748-6963
• DOI: 10.2217/nnm-2019-0431

To characterize a method to isolate glioma-derived extracellular vesicles (GEVs) and understand their role in immune system modulation and glioma progression.
GEVs were isolated by differential centrifugation from C6 cell supernatant and characterized by size and expression of CD9, HSP70, CD39 and CD73. The glioma model was performed by injecting C6 glioma cells into the right striatum of Wistar rats in the following groups: controls (C6 cells alone), coinjection (C6 cells + GEVs) and GEVs by intranasal administration followed by immune cells, tumor size and cells proliferation analyses.
GEVs presented uniform size (175 nm), expressed CD9, HSP70, CD39, CD73 and produced adenosine.
, we observed a reduction in tumor size, in cell proliferation (Ki-67) and in a regulatory cell marker (FoxP3).
GEVs, administered before or at tumor challenge, have antiproliferative properties and reduce regulatory cells in the glioma microenvironment.